NYSE · LLY
Eli Lilly and Company
$1,429.85+$56.15 (+4.09%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
NASDAQ · IMPL · USD
Stock price, earnings
Quote as of Dec 20, 2023, 08:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Impel Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Impel Pharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder. Impel is also progressing with INP107, an intranasal carbidopa/levodopa compound, which has already successfully concluded its Phase IIa clinical trial aimed at managing "OFF" episodes in Parkinson's disease patients. Initially established in 2008, the company was formerly known as Impel NeuroPharma, Inc. before rebranding to Impel Pharmaceuticals Inc. in April 2022. Its corporate headquarters are situated in Seattle, Washington.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2021 | Mar 24, 2022 | -$1.07-24.42% vs estimate | $577.00K-65.24% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,429.85+$56.15 (+4.09%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$0.41$0.00 (0.0%)
CohBar, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.41% below the high.
$0.34+$0.00 (+0.74%)
Timber Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.89% below the high.
$0.30+$0.30 (+100.0%)
Altamira Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.85% below the high.
$0.32-$0.17 (-34.28%)
InVivo Therapeutics Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 86.64% below the high.
$0.03$0.00 (0.0%)
Accelerate Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.37% below the high.
$0.66-$0.21 (-24.02%)
Acorda Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.27% below the high.
$0.07-$0.01 (-6.68%)
Bellicum Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.29% below the high.
